Volume 28, Number 3—March 2022
CME ACTIVITY - Research
Neutralizing Enterovirus D68 Antibodies in Children after 2014 Outbreak, Kansas City, Missouri, USA
Table 1
Serum neutralizing antibody positivity and titers for enterovirus D68 clades B1, B2, and D, by patient age group, Kansas City, Missouri, USA, 2017
Age group | No. patients | % Neutralizing antibody positive, median (range) neutralizing antibody titer* |
||
---|---|---|---|---|
B1 clade virus | B2 clade virus | D clade virus | ||
6–35 mo | 76 | 100, 7.83 (5.50–10.5) | 76.9, 3.17 (2.5–10.5) | 98.1, 5.5 (2.5–9.83) |
36–71 mo | 51 | 100, 9.17 (6.17–10.5) | 89.8, 6.00 (2.5–10.5) | 100, 6.5 (3.5–10.5) |
72 mo−10 y | 70 | 100, 9.50 (6.50–10.5) | 96.7, 8.83 (2.5–10.5) | 99.5, 8.17 (2.83–10.5) |
11–15 y | 69 | 100, 10.17 (6.5–10.5) | 99.3, 10.17 (2.5–10.5) | 100, 10.17 (3.83–10.5) |
>15 y | 34 | 100, 10.5 (5.83–10.5) | 100, 10.50 (5.5–10.5) | 100, 10.5 (4.5–10.5) |
Total | 300 | 100, 9.17 (5.5–10.5) | 84.6, 7.83 (2.5–10.5) | 99.6, 7.50 (2.5–10.5) |
*Antibody titers were measured by using the cell viability kit ATPlite (Perkin Elmer, http://www.perkinelmer.com); the titers shown are the log2 inverse dilution of the lowest antibody concentration with luminescent activity. Seronegative patients are included.
1All authors contributed equally to this article.